ASDCD: Antifungal Synergistic Drug Combination Database

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Chen, Xing ^a,b   Ren, Biao ^c,d   Chen, Ming ^e   Liu, Ming Xi ^b,c   Ren, Wei ^b,g   Wang, Quan Xin ^f   Zhang, Li Xin ^d,e   Yan, Gui Ying ^a,b  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d SOUTH CHINA SEA INSTITUTE OF OCEANOLOGY   (China)

^e INSTITUTE OF MICROBIOLOGY   (China)

^f UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^g Search Technology Center Asia   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; TRICAN; UNCLASSIFIED DRUG;

ANTIFUNGAL SYNERGISTIC DRUG COMBINATION DATABASE; ARTICLE; COMPUTER INTERFACE; DATA BASE; DRUG COMBINATION; DRUG COMBINATION DATABASE; DRUG POTENTIATION; DRUG RESEARCH; INTERNET; CHEMISTRY; DRUG DATABASE; DRUG EFFECTS; FUNGUS; HUMAN; METABOLISM; MICROBIOLOGY; MYCOSES; PATHOGENICITY;

ANTIFUNGAL AGENTS; DATABASES, PHARMACEUTICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUNGI; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MYCOSES;

EID: 84898487066     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086499     Document Type: Article

References (43)

1. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
2. Levinson AD (2010) Cancer therapy reform. Science 328: 137.
3. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, et al. (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 100: 7977-7982. (Pubitemid 36760080)
4. Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42. (Pubitemid 46014485)
5. Biavatti MW (2009) Synergy: an old wisdom, a new paradigm for pharmacotherapy. Brazilian Journal of Pharmaceutical Sciences 45: 371-378.
6. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466. (Pubitemid 44266307)
7. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122-129. (Pubitemid 40018235)
8. Bliss CI (1939) The toxicity of poisons applied jointly. Annals of Applied Biology 26: 585-615.
9. Hartman JLt, Garvik B, Hartwell L (2001) Principles for the buffering of genetic variation. Science 291: 1001-1004.
10. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285-290.
11. Borgert CJ, Borgert SA, Findley KC (2005) Synergism, antagonism, or additivity of dietary supplements: application of theory to case studies. Thromb Res 117: 123-132; discussion 145-151.
12. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385.
13. Jawetz E, Gunnison JB (1953) Antibiotic synergism and antagonism; an assessment of the problem. Pharmacol Rev 5: 175-192.
14. Krogstad D, Moellering RCJ, Lorian V (1986) Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins.
15. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460-466.
16. Chou TC (2008) Preclinical versus clinical drug combination studies. Leuk Lymphoma 49: 2059-2080.
17. Lee MS, Johansen L, Zhang YZ, Wilson A, Keegan M, et al. (2007) The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res 67: 11359-11367. (Pubitemid 350248563)
18. Biran A, Brownstein M, Haklai R, Kloog Y (2011) Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer 128: 691-701.
19. Yun O, Priotto G, Tong J, Flevaud L, Chappuis F (2010) NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 4: e720.
20. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, et al. (2010) Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro. PLoS One 5.
21. Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, et al. (2010) Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 9: 1399-1410.
22. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N (2011) Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25: 1314-1323.
23. Wei Y, Kadia T, Tong WG, Zhang M, Jia Y, et al. (2010) The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. Clinical Cancer Research 16: 3923-3932.
24. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, et al. (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17: 569-580.
25. Hama A, Sagen J (2012) Combination Drug Therapy for Pain following Chronic Spinal Cord Injury. Pain Research and Treatment 2012.
26. Chan E, Tan M, Xin JN, Sudarsanam S, Johnson DE (2010) Interactions between traditional Chinese medicines and Western therapeutics. Current Opinion in Drug Discovery Development 13: 50-65.
27. Chen X, Zhou H, Liu YB, Wang JF, Li H, et al. (2006) Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Br J Pharmacol 149: 1092-1103. (Pubitemid 44950812)
28. Sagar SM, Wong RK (2008) Chinese medicine and biomodulation in cancer patients - Part one. Curr Oncol 15: 42-48.
29. Zhu YP, Woerdenbag HJ (1995) Traditional Chinese Herbal Medicine. Pharmacy World Science 17: 103-112.
30. Molina JR, Adjei AA, Jett JR (2006) Advances in chemotherapy of non-small cell lung cancer. Chest 130: 1211-1219. (Pubitemid 44583755)
31. Raez LE, Lilenbaum R (2006) New developments in chemotherapy for advanced non-small cell lung cancer. Curr Opin Oncol 18: 156-161. (Pubitemid 43740436)
32. von Minckwitz G (2007) Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother 8: 485-495.
33. Liu Y, Hu B, Fu C, Chen X (2010) DCDB: drug combination database. Bioinformatics 26: 587-588.
34. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology 27: 659-666.
35. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. Journal of natural products 70: 461-477. (Pubitemid 46595760)
36. Zhang LX, Yan KZ, Zhang Y, Huang R, Bian J, et al. (2007) High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Natl Acad Sci U S A 104: 4606-4611. (Pubitemid 47186272)
37. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-906. (Pubitemid 351149842)
38. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
39. Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, et al. (2008) SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 36: D919-922. (Pubitemid 351149845)
40. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. New England Journal of Medicine 301: 126-131. (Pubitemid 10225854)
41. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA (2005) Combination treatment of invasive fungal infections. Clinical microbiology reviews 18: 163-194. (Pubitemid 40170667)
42. Rossi S, Hurley E, Abbott F (2006) Australian medicines handbook. Adelaide: Australian Medicines Handbook: 2-3.
43. Xu Y, Wang Y, Yan L, Liang RM, Dai BD, et al. (2009) Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation. J Proteome Res 8: 5296-5304.